Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined how conventional anti-tuberculosis drug therapy affects the intestinal microbiome. Researchers used 16S rRNA sequencing to longitudinally track microbial diversity and community composition in Mycobacterium tuberculosis-infected mice treated with the standard isoniazid-rifampin-pyrazinamide (HRZ) regimen. They also tested each antibiotic individually and in various combinations to identify which drug or drugs drove any observed changes.
Who was studied?
The study population was Mtb-infected mice, not human subjects. The abstract does not give an exact number of animals, but it describes longitudinal sampling across the treatment course and a post-treatment follow-up period of at least three months. Comparisons were made across mice receiving monotherapy, different combination therapies, and the full HRZ regimen.
What were the most important findings?
HRZ treatment caused only a transient dip in microbial diversity, but it triggered an immediate, marked, and reproducible shift in gut community structure that persisted throughout therapy and for at least three months after stopping treatment. Members of the order Clostridiales decreased in relative frequency during treatment, while the family Porphyromonadaceae increased afterward. Experiments isolating individual drugs identified rifampin as the major driver of these compositional alterations.
What are the greatest implications of this study?
Because this multi-drug regimen is administered to millions of people annually worldwide, a persistent, rifampin-driven dysbiosis lasting months beyond treatment could have broad public health relevance. The findings suggest that standard TB therapy leaves a durable signature on the gut microbiota rather than a transient one. This raises the question of whether such prolonged dysbiosis contributes to downstream health effects in treated patients, warranting further investigation in humans.